SCLERO.ORG
Search

Antibodies in Lupus

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
Overview
Anti-CII
Antiphospholipid (aPL)
C Reactive Protein (CRP)
NKG2A
Scl-70 (topo-I) (ATA)
Anti-SM

Overview

There are a wide variety of autoantibodies associated with lupus. Some of the antibodies are helpful in diagnosing the illness, while others are more useful in detecting disease activity or potential complications. (Also see Autoimmune Diseases and Overview of Lupus)

Elevated serum autoantibodies against co–inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new–onset systemic lupus erythematosus (SLE) patients. The current study indicates, for the first time, that the serum levels of co–inhibitor autoantibodies against PD-1 are elevated in new–onset SLE patients and are associated with disease activity in SLE. PubMed, Arthritis Res Ther, 2017 Mar 9;19(1):52.

Distinct antibody profile: a clue to primary antiphospholipid syndrome (PAPS) evolving into systemic lupus erythematosus (SLE)? The detection of a distinct subgroup of lupus-associated autoantibody in PAPS patients seems to be a hint to overt SLE disease, particularly in those patients with young age at diagnosis. PubMed, Clin Rheumatol, 2014 Jan 14. (Also see Antiphospholipid Syndrome)

Anti–CII Antibodies

Anti–CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus (SLE). Anti–dsDNA Abs and complement factors have been used as indicators of lupus activity and therefore, anti–CII Ab could be a novel indicator for monitoring activity of SLE. PubMed, Lupus, 06/05/2015.

Antiphospholipid Antibodies (aPL)

Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis (UEDVT). UEDVT could be the first clinical symptom of Antiphospholipid syndrome, and may be the first clinical manifestation of preceding the development of Systemic Lupus Erythematosus by several years. PubMed, Cent Eur J Immunol, 2015;40(3):307–310. (Also see Antiphospholipid Syndrome)

The role of antiphospholipid autoantibodies (aPL) in the cognitive deficits of patients with systemic lupus erythematosus (SLE). Results support the relationship between aPL and cognitive symptoms in SLE. PubMed, Lupus, 02/18/2015.

Cigarette smoking, antiphospholipid antibodies (aPL) and vascular events (VE) in Systemic Lupus Erythematosus (SLE). Among ever regular smokers who were aPL positive, there was a strikingly high frequency of former VE and the underlying mechanisms and temporality between smoking, aPL and VE need further investigations. PubMed, Ann Rheum Dis, 2014 Apr 1. (Also see Antiphospholid Syndrome)

C Reactive Protein (Anti-CRP)

Anti-CRP antibodies in systemic lupus erythematosus. Anti-CRP autoantibodies, which are found in 35 to 40% of SLE patients, increase the cardiovascular risk by interacting with the monomeric (degraded) form of CRP. PubMed, Joint Bone Spine.

NKG2A Antibodies

Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus (SLE). Anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies have the capacity to deplete certain NK cell subsets and interfere with particular NK cell function and may promote the pathogenesis of SLE. PubMed, Arthritis Rheumatol, 2015 Apr;67(4):1000-11.

Scl-70 (topo-I)(ATA)

Topoisomerase I (topo-1) in Human Disease Pathogenesis and Treatments. In this review, we will summarize our current understandings on how TOP1 contributes to human diseases and how its activity is targeted for disease treatments. PubMed, Genomics Proteomics Bioinformatics, 2016 Jun;14(3):166-71.

SM (Anti-SM antibodies)

Anti–Sm is associated with the early poor outcome of lupus nephritis. Our data suggest that anti–Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy–proven lupus nephritis during the follow–up period. PubMed, Int J Rheum Dis, 04/29/2016. (Also see Symptoms and Complications of Lupus)

Go to Treatments for Lupus
 
Recent Donors
See ISN News for recent donors, including memorials for
Christine Kane, Joleen M. Cascaden.
 

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 1-800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

 
The most important thing in the world to know about scleroderma is sclero.org!
Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.